Authors

Andre Goy, MD, MS, John Theurer Cancer Center - Hackensack University Medical Center

Latest:

Recommendations For Future Clinical Trials in R/R MM

Panelists discuss how insights from ASH 2024 highlight the need for personalized treatment strategies, improved trial designs, and greater inclusion of diverse patient populations in future clinical trials for relapsed/refractory multiple myeloma (R/R MM).

Andre H. Goy, MD, MS

Latest:

Dr. Goy on the Potential Utility of BTK Inhibitors as Maintenance in MCL

Andre H. Goy, MD, discusses the potential utility of BTK inhibitors as maintenance therapy in mantle cell lymphoma.

Andrea Apolo, MD

Latest:

Dr Apolo on Adjuvant Pembrolizumab in Muscle-Invasive Urothelial Carcinoma

Andrea B. Apolo, MD, discusses the AMBASSADOR Alliance A031501 trial of adjuvant pembrolizumab in locally advanced/muscle-invasive urothelial carcinoma.

Andrea B. Apolo, MD, National Cancer Institute

Latest:

Sequencing Later-Line Therapies for Metastatic Urothelial Carcinoma

A brief review of second-line and subsequent treatment strategies in metastatic urothelial carcinoma and novel therapies being explored in this space.

Andrea Cercek, MD

Latest:

Novel Therapies in HER2-Amplified Metastatic Colorectal Cancer

Dr Andrea Cercek reviews key clinical trials in HER2-amplified colorectal cancer treatment and considers how the approval of new therapies will impact the current treatment landscape.

Andrea Cercek, MD, Memorial Sloan Kettering Cancer Center

Andrea De Censi, MD

Latest:

Dr. De Censi on the Hope for Biosimilars in the United States

Andrea De Censi, MD, director of the medical oncology unit at the National Hospital E.O. Ospedali Galliera–SC Oncologia Medica in Genoa, Italy, discusses the hope for biosimilars in the United States.

Andrea Merrill, MD

Latest:

Patients Are a Virtue

It is 4:45 am on a Saturday in June.

Andrea Necchi, MD

Andrea Necchi, MD, is an associate professor at Vita-Salute Raffaele University and the head of genitourinary medical oncology at IRCCS San Raffaele Hospital and Scientific Institute in Italy.

Latest:

Oncology Experts Dive Into Top Data From ESMO 2025

At the 2025 ESMO Congress, leading oncologists reflected on data expected to redefine practice across breast, genitourinary, and gynecologic malignancies.

Andrea Price, APN

Latest:

Adding CAR T-Cell Therapy to the Electronic Medical Record

Andrea Price, APN, discusses adding CAR T-cell therapy to the electronic medical record.

Andrea Richardson, MD, PhD, Sibley Memorial Hospital

Andrea Sboner, MS, PhD

Latest:

The Applications of a Mixed Reality Laboratory

Andrea Sboner, MS, PhD, assistant professor of computational genomics in computational biomedicine and of pathology and laboratory medicine, Weill Cornell Medicine, discusses the applications of a mixed reality laboratory.

Andrea V. Barrio, MD, FACS

Latest:

Dr. Barrio on Neoadjuvant Chemo to De-Escalate Axillary Node Dissection in Breast Cancer

Andrea V. Barrio, MD, FACS, discusses how the use of neoadjuvant chemotherapy can help de-escalate axillary node dissection in select patients with breast cancer. Dissection can be a morbid procedure with longterm risks of lymphoma, impacting the quality of life for many patients.

Andrea Wang-Gillam, MD, PhD

Latest:

Dr. Wang-Gillam on Next Steps With Defactinib Combo in Pancreatic Ductal Adenocarcinoma

Andrea Wang-Gillam, MD, PhD, discusses potential next steps with a novel combination regimen in pancreatic ductal adenocarcinoma.

Andrea Wang-Gilliam, MD, PhD, Washington University

Andreas du Bois, MD

Latest:

Dr. du Bois on Pazopanib in Advanced Ovarian Cancer

Andreas du Bois, MD, from Kliniken Essen Mitte in Essen, Germany, discusses a phase III trial exploring the effectiveness of treatment with maintenance pazopanib for patients with advanced ovarian cancer.

Andreas du Bois, MD, PhD

Latest:

Dr. du Bois on the Potential Impact of Cytoreductive Surgery in Ovarian Cancer

Andreas du Bois, MD, PhD, a professor of gynecologic oncology at Kliniken Essen Mitte, discusses the potential impact of cytoreductive surgery in ovarian cancer.

Andreas Hochhaus, MD

Latest:

Dr. Hochhaus on TFS With Nilotinib in Patients With CML

Andreas Hochhaus, MD, professor of Internal Medicine, Hematology and Oncology, interim head of the Department of Hematology and Medical Oncology, University Medical Center Jena in Germany, discusses results of the phase II ENESTFreedom study, which examined treatment-free survival (TFS) in patients with chronic myeloid leukemia (CML) who received frontline nilotinib (Tasigna).

Andreas Kaubisch, MD

Latest:

Dr. Kaubisch on the REACH Trials in HCC

Andreas Kaubisch, MD, discusses the phase III REACH and REACH-2 trials in advanced hepatocellular carcinoma.